Retatrutide vs Tirzepatide vs Semaglutide: Comparison of Mechanism, Study Data and Status
Factual comparison of Retatrutide, Tirzepatide and Semaglutide focusing on receptor profile, weight reduction, side effects, cardiovascular data and approval status.
Research on incretin-based peptides has advanced considerably in recent years. Selective GLP-1 receptor agonists were followed by dual agonists and later triple agonists. Among the relevant representatives are Semaglutide, Tirzepatide and Retatrutide. They differ primarily in their receptor profile and the maturity of clinical evidence.
This article compares the three peptides based on published study data and official manufacturer and regulatory information. The focus is on mechanisms of action, clinical outcomes, side effect profiles, pharmacokinetics and current development status. All information is provided exclusively for scientific purposes.
The Three Generations at a Glance
The classification into "generations" is not an official taxonomy, but is commonly used as orientation in practice:
- 1st Generation: Selective GLP-1 receptor agonists such as Semaglutide (Novo Nordisk). Act via the GLP-1 receptor.
- 2nd Generation: Dual agonists such as Tirzepatide (Eli Lilly). Activate GLP-1 and GIP receptors.
- 3rd Generation: Triple agonists such as Retatrutide (Eli Lilly, LY-3437943). Activate GLP-1, GIP and glucagon receptors.
With each additional receptor, the metabolic profile shifts. The central research question remains whether broader receptor activation leads to consistently better outcomes and how this affects tolerability, safety and application area.
Mechanism of Action: Single vs Dual vs Triple Agonist
GLP-1 Receptor (all three peptides)
The GLP-1 receptor is the common denominator of all three compounds. Its activation produces:
- Glucose-dependent insulin secretion
- Inhibition of glucagon release (postprandial)
- Delayed gastric emptying
- Central appetite reduction via hypothalamic signaling pathways
GIP Receptor (Tirzepatide and Retatrutide)
Glucose-dependent Insulinotropic Polypeptide (GIP) complements GLP-1 activity through:
- Improved insulin sensitivity
- Modulation of fat metabolism
- Potential effects on bone metabolism
- Enhancement of incretin-mediated satiety signals
Glucagon Receptor (Retatrutide only)
The additional glucagon receptor agonism distinguishes Retatrutide from the other two molecules. Despite the classical classification of glucagon as a catabolic hormone, preclinical and clinical data show that controlled activation can have metabolic effects of independent relevance:
- Increased energy expenditure and thermogenesis
- Promotion of hepatic lipolysis and fat oxidation
- Reduction of liver fat content
- Elevation of basal metabolic rate
Comparison Table: Receptor Pharmacology
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1 Receptor | Selective agonist | Agonist | Agonist |
| GIP Receptor | No | Agonist | Agonist |
| Glucagon Receptor | No | No | Agonist |
| Receptor Class | Single Agonist | Dual Agonist | Triple Agonist |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Molecule Type | GLP-1 analogue | GIP-based peptide | GIP-based peptide |
Study Results Compared: Weight Reduction
Percentage weight reduction is one of the most frequently compared variables. However, direct comparisons remain limited because study design, population, dose and observation period differ considerably.
Semaglutide: STEP Trial Program
The STEP trials form a central evidence base for Semaglutide in obesity research:
- STEP 1 (NEJM, 2021): 2.4 mg subcutaneous, weekly. Mean weight reduction of 14.9% after 68 weeks in participants with obesity without diabetes.
- STEP 2 (Lancet, 2021): In participants with type 2 diabetes, Semaglutide 2.4 mg achieved weight reduction of 9.6% after 68 weeks.
- STEP 5 (Nature Medicine, 2022): Long-term data over 104 weeks confirmed sustained weight reduction of approximately 15.2%.
Tirzepatide: SURPASS and SURMOUNT Trials
The evidence profile for Tirzepatide comes from diabetes and obesity studies:
- SURPASS-2 (NEJM, 2021; Lilly, June 25, 2021): Head-to-head comparison against injectable Semaglutide 1 mg in type 2 diabetes. All three Tirzepatide doses were superior to Semaglutide in HbA1c and weight reduction.
- SURMOUNT-1 (NEJM, 2022): Tirzepatide 15 mg achieved a mean weight reduction of 20.9% after 72 weeks in participants with obesity without diabetes.
- SURMOUNT-2 (Lancet, 2023): In participants with type 2 diabetes, approximately 14.7% weight reduction was achieved with 15 mg.
- SURMOUNT-5 (2024/2025): Direct comparison against Semaglutide 2.4 mg in an obesity population. Tirzepatide achieved 20.2% weight reduction versus 13.7% under Semaglutide after 72 weeks. This study was not the first head-to-head trial against Semaglutide overall, but a later direct comparison in this setting.
Retatrutide: Phase 2 Study and TRIUMPH-4
The clinical data situation for Retatrutide is more recent and less mature:
- Phase 2 Study (NEJM, 2023): 338 participants, 48 weeks. The 12 mg group achieved a mean weight reduction of 24.2%. The weight curve had not yet reached a clear plateau at the end of the observation period.
- TRIUMPH-4 (Topline announcement, December 2025): Retatrutide achieved weight reduction of up to 28.7% in a phase 3 study on obesity with knee osteoarthritis and simultaneously reduced knee pain. Additional Phase 3 data are expected for 2026.
Comparison Table: Weight Reduction
| Study | Peptide | Dose | Duration | Weight Reduction | Population |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide | 2.4 mg/week | 68 weeks | ~14.9% | Obesity, no diabetes |
| SURMOUNT-1 | Tirzepatide | 15 mg/week | 72 weeks | ~20.9% | Obesity, no diabetes |
| SURMOUNT-5 | Tirzepatide | 10/15 mg vs. Semaglutide 2.4 mg | 72 weeks | 20.2% vs. 13.7% | Direct comparison in obesity |
| Phase 2 | Retatrutide | 12 mg/week | 48 weeks | ~24.2% | Obesity, no diabetes |
| TRIUMPH-4 | Retatrutide | Highest doses | Phase 3 | ~28.7% | Obesity + osteoarthritis |
Important note: The values are not directly comparable because populations and study designs differ.
Side Effect Profile Compared
Gastrointestinal side effects are the most common adverse events for all three peptides. This is consistent with GLP-1-mediated influence on gastric emptying and appetite regulation.
Common GI Side Effects
| Side Effect | Semaglutide 2.4 mg | Tirzepatide 15 mg | Retatrutide 12 mg |
|---|---|---|---|
| Nausea | ~44% | ~31% | ~45% |
| Diarrhea | ~30% | ~23% | ~39% |
| Vomiting | ~24% | ~12% | ~20% |
| Constipation | ~24% | ~11% | ~16% |
| Discontinuation due to AE | ~7% | ~6% | ~6% |
Some observations from published data:
- Semaglutide has a well-characterized GI profile from extensive clinical use. Complaints often occur during the titration phase and frequently diminish over time.
- Tirzepatide showed strong efficacy in several programs with an overall comparable GI profile. Whether GIP agonism clinically modifies nausea remains an area of ongoing research.
- Retatrutide also showed a predominantly GI-characterized side effect profile in Phase 2. Robust long-term data from Phase 3 are still pending.
Serious adverse events were infrequent overall in the large programs. Most GI complaints were described as mild to moderate.
Pharmacokinetics: Half-life and Dosing
All three peptides were developed for weekly subcutaneous administration. The long half-lives are achieved through structural modifications such as fatty acid side chains with albumin binding.
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Half-life | ~7 days | ~5 days | ~6 days |
| Administration | Subcutaneous, 1x/week | Subcutaneous, 1x/week | Subcutaneous, 1x/week |
| Tmax | 1-3 days | 8-72 hours | 12-72 hours |
| Dose titration | 4-weekly increase | 4-weekly increase | 4-weekly increase |
| Target dose | 2.4 mg (obesity) | 5/10/15 mg | 8/9/12 mg (study-dependent) |
| Bioavailability (s.c.) | ~89% | ~80% | Data pending |
The half-lives are long enough to enable stable exposure over seven days. Clinically, all three compounds are used or investigated with stepwise titration to improve GI tolerability.
Further Indications Beyond Weight Research
Research on GLP-1-based peptides is not limited to weight reduction. Differences between the three molecules are particularly evident in the maturity of evidence.
MASLD/NASH
Metabolically associated steatotic liver disease (MASLD, formerly NAFLD/NASH) is an active research field:
- Semaglutide: Showed histological improvements in NASH in studies; published results suggest clinical activity, but the regulatory role remains limited.
- Tirzepatide: Investigated in the SYNERGY-NASH study among others and showed relevant effects on liver fat and histological endpoints.
- Retatrutide: In a Phase 2a study in Nature Medicine 2024, liver fat content normalized after 24 weeks in 79% of participants on 8 mg and 86% on 12 mg (PubMed).
The pronounced effect of Retatrutide on liver fat is a plausible indicator of a contribution from the additional glucagon receptor agonism. It should, however, be interpreted on the basis of Phase 2 data published to date.
Type 2 Diabetes
| Peptide | Approval for Diabetes | HbA1c Reduction (approx.) |
|---|---|---|
| Semaglutide | Approved (Ozempic) | 1.5-1.8% |
| Tirzepatide | Approved (Mounjaro) | 2.0-2.4% |
| Retatrutide | Phase 3 | ~2.0% (Phase 2) |
Tirzepatide showed advantages in HbA1c and weight in published direct comparisons against Semaglutide 1 mg in type 2 diabetes (SURPASS-2, NEJM 2021).
Cardiovascular Research
- Semaglutide: The SELECT study showed in 2023 a 20% reduction in major cardiovascular events (MACE) in patients with obesity and pre-existing cardiovascular disease.
- Tirzepatide: Alongside the ongoing SURPASS-CVOT study, completed clinical outcome data from SUMMIT are already available. Lilly reported on August 1, 2024 that Tirzepatide in HFpEF and obesity reduced the risk of the combined endpoint of heart failure events and cardiovascular death by 38% versus placebo (Lilly SUMMIT).
- Retatrutide: Cardiovascular and renal outcome studies are part of the ongoing Phase 3 program; robust endpoint data are not yet available.
Semaglutide continues to have the most extensive published MACE evidence. It is, however, no longer accurate to describe Semaglutide as the only one of these three peptides with completed cardiovascular outcomes, because clinical outcome data from SUMMIT have been reported for Tirzepatide.
Further Areas Under Investigation
- Sleep apnea: Tirzepatide is not only under investigation; Zepbound was approved by the FDA on December 20, 2024 for moderate to severe obstructive sleep apnea in adults with obesity (FDA).
- Chronic kidney disease: The FLOW study on Semaglutide was published in 2024 in the NEJM (NEJM). In addition, the FDA label for Ozempic now includes reduction of eGFR decline, end-stage renal disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (FDA PDF).
- Osteoarthritis: TRIUMPH-4 showed, according to the topline announcement, significant pain reduction in knee osteoarthritis under Retatrutide.
Approval Status (as of March 2026)
| Peptide | Obesity | Type 2 Diabetes | Approval Year | Phase |
|---|---|---|---|---|
| Semaglutide | Approved (Wegovy) | Approved (Ozempic) | 2021/2017 | Approved |
| Tirzepatide | Approved (Zepbound) | Approved (Mounjaro) | 2023/2022 | Approved |
| Retatrutide | Not approved | Not approved | Pending | Phase 3 |
Semaglutide and Tirzepatide are approved for type 2 diabetes; both also have approved obesity products. Retatrutide remains an investigational compound in the Phase 3 program.
For researchers it is important: Retatrutide is not approved and not freely available on the general market. Lilly states that Retatrutide is legally available only to participants in Lilly studies; no one outside a Lilly-sponsored clinical trial should use a product described as Retatrutide (Lilly FAQ).
Which Peptide for Which Research Question?
Suitability depends on the specific research question. A useful division of roles looks like this:
GLP-1 Signaling Pathways and Basic Research
Semaglutide is a well-characterized reference compound for selective GLP-1 receptor effects. The broad clinical database facilitates the interpretation of experimental results.
Dual Incretin Signaling (GLP-1 + GIP)
Tirzepatide is suitable for questions in which the additional contribution of the GIP receptor is to be investigated, for example in insulin sensitivity, weight dynamics or fat metabolism.
Triple Agonism and Glucagon Research
Retatrutide is relevant for research questions involving combined GLP-1, GIP and glucagon receptor activation, particularly in:
- Contribution of the glucagon receptor to metabolic regulation
- Research on liver fat metabolism and MASLD
- Comparison of dual vs. triple receptor activation
- Thermogenesis and energy expenditure research
Decision Guide
| Research Question | Suitable Peptide |
|---|---|
| GLP-1 signaling pathway in isolation | Semaglutide |
| GLP-1/GIP synergism | Tirzepatide |
| Glucagon contribution in triple agonism | Retatrutide |
| Liver fat metabolism | Retatrutide |
| Comparison: Single vs. Dual vs. Triple | All three |
| Cardiovascular mechanisms | Semaglutide or Tirzepatide, depending on endpoint |
| Insulin sensitivity and beta-cell function | Tirzepatide |
Summary
The comparison of Semaglutide, Tirzepatide and Retatrutide illustrates the progression from selective GLP-1 agonism through dual incretin activation to triple agonism. The data available to date support increasing efficacy in weight and metabolic parameters, while the maturity and robustness of evidence differ considerably.
Semaglutide has the broadest published clinical and outcome evidence in cardiovascular and renal endpoints. Tirzepatide has both robust obesity and diabetes data as well as clinical outcome data from SUMMIT. Retatrutide shows clear effects in Phase 2 and initial Phase 3 announcements, but remains an investigational compound until further published endpoint data are available.
All three molecules are relevant for research, but for different reasons: Semaglutide as an established GLP-1 reference, Tirzepatide as a dual agonist with a clinically broad dataset and Retatrutide as a triple agonist with additional glucagon signaling. Sound interpretation requires direct source citations and the distinction between published data, topline announcements and ongoing studies.
This article is provided exclusively for scientific research purposes. Cited study data refer to peer-reviewed publications, FDA communications and official manufacturer information.
Disclaimer: FOR RESEARCH USE ONLY. All products from PeptidesDirect are intended exclusively for in vitro research and laboratory use. Not for human consumption. Not for in vivo applications. By purchasing, you confirm that the products are not intended for ingestion or any other application in humans.